December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24
Oct 14, 2024, 12:36

Updated data of KEYNOTE-716 and CheckMate 76K studies at ESMO24

The European Society for Medical Oncology (ESMO) shared a post on X:

“At ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with melanoma.”

Read further.

More posts featuring ESMO.